NA Acute LymphocyticLymphoblastic Leukemia (ALL) Diagnostics Market

Description

List of Tables

The North America Acute Lymphocytic/Lymphoblastic Leukemia (ALL) diagnostics market is projected to register a substantial CAGR of 7.6% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2020, the base year of calculation is 2021, and the forecast period is 2023 to 2030

Market Segmentation:

North America Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Diagnostics Market, By Product Type (Instruments and Consumables & Accessories), Test Type (Imaging Test, Biopsy, Blood Test, and Others), Cancer Type (B-cell Lymphoblastic Leukemia/Lymphoma, and T-cell Lymphoblastic Leukemia), Age Group (Below 21, 21-29, 30-65, 65 and Above), Gender (Male and Female) End User (Hospitals, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, and Others), Distribution Channel (Direct Tender, Retail Sales), Country (U.S., Canada, Mexico) Industry Trends and Forecast to 2030.

Some of the major factors contributing to the growth of the North America Acute Lymphocytic/Lymphoblastic Leukemia (ALL) diagnostics market are:

Rise in prevalence and incidence of leukemia cancer

Increase in healthcare expenditure for cancer diagnosis and treatment

Market Players:

Some of the major players operating in the North America Acute Lymphocytic/Lymphoblastic Leukemia (ALL) diagnostics market are:

F. Hoffmann-La Roche Ltd.

Thermo Fisher Scientific, Inc.

QIAGEN

Abbott

Siemens Medical Solutions USA, Inc.

Merck KGaA

Hologic, Inc.

bioMerieux SA

Agilent Technologies, Inc.

DiaSorin S.p.A.

Illumina, Inc.

Myriad Genetics, Inc.

Quest Diagnostics Incorporated.

Bio-Rad Laboratories, Inc.

Koninklijke Philips N.V.

Exact Sciences Corporation

Time Medical Holding

Michelson Diagnostics Ltd.

MinFound Medical Systems Co., Ltd

1 INTRODUCTION 54

1.1 OBJECTIVES OF THE STUDY 54
1.2 MARKET DEFINITION 54
1.3 OVERVIEW OF NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET 54
1.4 LIMITATIONS 56
1.5 MARKETS COVERED 57

2 MARKET SEGMENTATION 60

2.1 MARKETS COVERED 60
2.2 GEOGRAPHICAL SCOPE 61
2.3 YEARS CONSIDERED FOR THE STUDY 62
2.4 CURRENCY AND PRICING 62
2.5 DBMR TRIPOD DATA VALIDATION MODEL 63
2.6 MULTIVARIATE MODELLING 66
2.7 PRODUCT TYPE LIFELINE CURVE 66
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 67
2.9 DBMR MARKET POSITION GRID 68
2.10 MARKET TESTING TYPE COVERAGE GRID 70
2.11 VENDOR SHARE ANALYSIS 71
2.12 SECONDARY SOURCES 72
2.13 ASSUMPTIONS 72

3 EXECUTIVE SUMMARY 73

4 PREMIUM INSIGHTS 76

4.1 PESTEL ANALYSIS 77
4.2 PORTER'S FIVE FORCES 78
4.3 INDUSTRY INSIGHTS 79

5 EPIDEMIOLOGY 81

6 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, REGULATIONS 82

7 MARKET OVERVIEW 85

7.1 DRIVERS 87
- 7.1.1 NOVEL TECHNOLOGICAL ADVANCEMENTS IN LEUKEMIA DIAGNOSTICS 87
- 7.1.2 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS 87
- 7.1.3 INCREASE IN AWARENESS REGARDING LEUKEMIA CANCER 88
- 7.1.4 GROWING PREVALENCE OF LEUKEMIA CANCER 88
7.2 RESTRAINTS 90
- 7.2.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF LEUKEMIA DIAGNOSTIC PRODUCTS 90
- 7.2.2 LATE DIAGNOSIS AND POOR PROGNOSIS OF LEUKEMIA 91
7.3 OPPORTUNITIES 91
- 7.3.1 INCREASE IN DIAGNOSTIC PRODUCTS FOR LEUKEMIA 91
- 7.3.2 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 92
- 7.3.3 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTICS 92
7.4 CHALLENGES 93
- 7.4.1 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES 93
- 7.4.2 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 94

8 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE 95

8.1 OVERVIEW 96
8.2 INSTRUMENTS 99
- 8.2.1 BIOPSY INSTRUMENTS 100
  - 8.2.1.1 BONE MARROW BIOPSY 100
  - 8.2.1.2 NEEDLE BIOPSY 100
  - 8.2.1.3 SURGEON BIOPSY 101
  - 8.2.1.4 OTHERS 101
- 8.2.2 PATHOLOGY-BASED INSTRUMENTS 101
  - 8.2.2.1 PCR INSTRUMENTS 101
  - 8.2.2.2 SLIDE STAINING SYSTEMS 101
  - 8.2.2.3 TISSUE PROCESSING SYSTEMS 101
  - 8.2.2.4 CELL PROCESSORS 102
  - 8.2.2.5 OTHER PATHOLOGY-BASED INSTRUMENTS 102
- 8.2.3 IMAGING INSTRUMENTS 102
  - 8.2.3.1 ULTRASOUND SYSTEMS 102
  - 8.2.3.2 CT SYSTEMS 102
  - 8.2.3.3 MRI SYSTEMS 102
  - 8.2.3.4 OTHERS 103
- 8.2.4 OTHERS 103
8.3 CONSUMABLES & ACCESSORIES 103
- 8.3.1 KITS 104
  - 8.3.1.1 PCR KITS 104
  - 8.3.1.2 DNA POLYMERASE KITS 104
  - 8.3.1.3 NUCLEIC ACID ISOLATION KITS 104
  - 8.3.1.4 OTHERS 105
- 8.3.2 REAGENTS 105
  - 8.3.2.1 ASSAYS 105
  - 8.3.2.2 BUFFERS 105
  - 8.3.2.3 PRIMERS 105
  - 8.3.2.4 OTHERS 105
- 8.3.3 PROBES 106
- 8.3.4 OTHER CONSUMABLES 106

9 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE 107

9.1 OVERVIEW 108
9.2 BIOPSY 111
- 9.2.1 BONE MARROW BIOPSY 112
- 9.2.2 NEEDLE BIOPSY 112
- 9.2.3 SURGEON BIOPSY 112
- 9.2.4 OTHERS 112
9.3 BLOOD TEST 113
- 9.3.1 BLOOD CHEMISTRY TESTS 114
- 9.3.2 COMPLETE BLOOD COUNT (CBC) 114
- 9.3.3 OTHERS 114
9.4 IMAGING TEST 114
- 9.4.1 COMPUTED TOMOGRAPHY (CT) SCAN 115
- 9.4.2 MRI 115
- 9.4.3 POSITRON EMISSION TOMOHRAPHY (PET) SCAN 116
- 9.4.4 OTHERS 116
9.5 OTHERS 116

10 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE 117

10.1 OVERVIEW 118
10.2 B-CELL LYMPHOBLASTIC LEUKEMIA/LYMPHOMA 121
- 10.2.1 EARLY PRE-B ALL 122
- 10.2.2 COMMON ALL 122
- 10.2.3 PRE-B ALL 122
- 10.2.4 MATURE B-CELL ALL 122
10.3 T-CELL LYMPHOBLASTIC LEUKEMIA 122
- 10.3.1 PRE-T ALL 123
- 10.3.2 MATURE T-CELL ALL 123

11 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY AGE GROUP 124

11.1 OVERVIEW 125
11.2 BELOW 21 128
11.3 21-29 129
11.4 30-65 130
11.5 65 AND ABOVE 131

12 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY GENDER 132

12.1 OVERVIEW 133
12.2 MALE 136
12.3 FEMALE 137

13 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY END USER 138

13.1 OVERVIEW 139
13.2 HOSPITALS 142
13.3 ASSOCIATED LABS 142
13.4 INDEPENDENT DIAGNOSTIC LABORATORIES 143
13.5 DIAGNOSTIC IMAGING CENTERS 144
13.6 CANCER RESEARCH INSTITUTES 144
13.7 OTHERS 145

14 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 146

14.1 OVERVIEW 147
14.2 DIRECT TENDER 150
14.3 RETAIL SALES 151

15 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION 152

15.1 NORTH AMERICA 153
- 15.1.1 U.S. 165
- 15.1.2 CANADA 171
- 15.1.3 MEXICO 177

16 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, COMPANY LANDSCAPE 183

16.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 183

17 SWOT ANALYSIS 184

18 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET 185

18.1 F. HOFFMANN-LA ROCHE LTD. 185
- 18.1.1 COMPANY SNAPSHOT 185
- 18.1.2 REVENUE ANALYSIS 185
- 18.1.3 COMPANY SHARE ANALYSIS 186
- 18.1.4 PRODUCT PORTFOLIO 186
- 18.1.5 RECENT DEVELOPMENT 186
18.2 THERMO FISHER SCIENTIFIC INC. 187
- 18.2.1 COMPANY SNAPSHOT 187
- 18.2.2 REVENUE ANALYSIS 187
- 18.2.3 COMPANY SHARE ANALYSIS 188
- 18.2.4 PRODUCT PORTFOLIO 188
- 18.2.5 RECENT DEVELOPMENT 188
18.3 QIAGEN 189
- 18.3.1 COMPANY SNAPSHOT 189
- 18.3.2 REVENUE ANALYSIS 189
- 18.3.3 COMPANY SHARE ANALYSIS 190
- 18.3.4 PRODUCT PORTFOLIO 190
- 18.3.5 RECENT DEVELOPMENT 190
18.4 ABBOTT 191
- 18.4.1 COMPANY SNAPSHOT 191
- 18.4.2 REVENUE ANALYSIS 191
- 18.4.3 COMPANY SHARE ANALYSIS 192
- 18.4.4 PRODUCT PORTFOLIO 192
- 18.4.5 RECENT DEVELOPMENT 192
18.5 SIEMENS MEDICAL SOLUTIONS USA, INC. 193
- 18.5.1 COMPANY SNAPSHOT 193
- 18.5.2 REVENUE ANALYSIS 193
- 18.5.3 COMPANY SHARE ANALYSIS 194
- 18.5.4 PRODUCT PORTFOLIO 194
- 18.5.5 RECENT DEVELOPMENT 194
18.6 MERCK KGAA 195
- 18.6.1 COMPANY SNAPSHOT 195
- 18.6.2 REVENUE ANALYSIS 195
- 18.6.3 PRODUCT PORTFOLIO 196
- 18.6.4 RECENT DEVELOPMENT 196
18.7 HOLOGIC INC. 197
- 18.7.1 COMPANY SNAPSHOT 197
- 18.7.2 REVENUE ANALYSIS 197
- 18.7.3 PRODUCT PORTFOLIO 198
- 18.7.4 RECENT DEVELOPMENT 198
18.8 AGILENT TECHNOLOGIES, INC. 199
- 18.8.1 COMPANY SNAPSHOT 199
- 18.8.2 REVENUE ANALYSIS 199
- 18.8.3 PRODUCT PORTFOLIO 200
- 18.8.4 RECENT DEVELOPMENT 200
18.9 BD 201
- 18.9.1 COMPANY SNAPSHOT 201
- 18.9.2 REVENUE ANALYSIS 201
- 18.9.3 PRODUCT PORTFOLIO 202
- 18.9.4 RECENT DEVELOPMENT 202
18.10 BIOMERIEUX SA 203
- 18.10.1 COMPANY SNAPSHOT 203
- 18.10.2 REVENUE ANALYSIS 203
- 18.10.3 PRODUCT PORTFOLIO 204
- 18.10.4 RECENT DEVELOPMENTS 204
18.11 BIO-RAD LABORATORIES, INC. 205
- 18.11.1 COMPANY SNAPSHOT 205
- 18.11.2 REVENUE ANALYSIS 205
- 18.11.3 PRODUCT PORTFOLIO 206
- 18.11.4 RECENT DEVELOPMENT 206
18.12 DIASORIN S.P.A. 207
- 18.12.1 COMPANY SNAPSHOT 207
- 18.12.2 REVENUE ANALYSIS 207
- 18.12.3 PRODUCT PORTFOLIO 208
- 18.12.4 RECENT DEVELOPMENTS 208
18.13 EXACT SCIENCE CORPORATION 209
- 18.13.1 COMPANY SNAPSHOT 209
- 18.13.2 REVENUE ANALYSIS 209
- 18.13.3 PRODUCT PORTFOLIO 210
- 18.13.4 RECENT DEVELOPMENT 210
18.14 ILLUMINA, INC. 211
- 18.14.1 COMPANY SNAPSHOT 211
- 18.14.2 REVENUE ANALYSIS 211
- 18.14.3 PRODUCT PORTFOLIO 212
- 18.14.4 RECENT DEVELOPMENT 212
18.15 KONINKLIJKE PHILIPS N.V. 213
- 18.15.1 COMPANY SNAPSHOT 213
- 18.15.2 REVENUE ANALYSIS 213
- 18.15.3 PRODUCT PORTFOLIO 214
- 18.15.4 RECENT DEVELOPMENT 214
18.16 MEDONICA CO. LTD 215
- 18.16.1 COMPANY SNAPSHOT 215
- 18.16.2 PRODUCT PORTFOLIO 215
- 18.16.3 RECENT DEVELOPMENT 215
18.17 MICHAEL DIAGNOSTICS LTD 216
- 18.17.1 COMPANY SNAPSHOT 216
- 18.17.2 PRODUCT PORTFOLIO 216
- 18.17.3 RECENT DEVELOPMENT 216
18.18 MINFOUND MEDICAL SYSTEMS CO., LTD 217
- 18.18.1 COMPANY SNAPSHOT 217
- 18.18.2 PRODUCT PORTFOLIO 217
- 18.18.3 RECENT DEVELOPMENT 217
18.19 MYRIAD GENETICS, INC. 218
- 18.19.1 COMPANY SNAPSHOT 218
- 18.19.2 REVENUE ANALYSIS 218
- 18.19.3 PRODUCT PORTFOLIO 219
- 18.19.4 RECENT DEVELOPMENT 219
18.20 PLEXBIO 220
- 18.20.1 COMPANY SNAPSHOT 220
- 18.20.2 PRODUCT PORTFOLIO 220
- 18.20.3 RECENT DEVELOPMENTS 220
18.21 QUEST DIAGNOSTICS INCORPORATED 221
- 18.21.1 COMPANY SNAPSHOT 221
- 18.21.2 REVENUE ANALYSIS 221
- 18.21.3 PRODUCT PORTFOLIO 222
- 18.21.4 RECENT DEVELOPMENTS 222
18.22 STERNMED GMBH 223
- 18.22.1 COMPANY SNAPSHOT 223
- 18.22.2 PRODUCT PORTFOLIO 223
- 18.22.3 RECENT DEVELOPMENTS 223
18.23 TIME MEDICAL HOLDING 224
- 18.23.1 COMPANY SNAPSHOT 224
- 18.23.2 PRODUCT PORTFOLIO 224
- 18.23.3 RECENT DEVELOPMENT 224

19 QUESTIONNAIRE 225

20 RELATED REPORTS 229

LIST OF FIGURES

FIGURE 1 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: SEGMENTATION 27
FIGURE 2 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: DATA TRIANGULATION 30
FIGURE 3 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: DROC ANALYSIS 31
FIGURE 4 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS 32
FIGURE 5 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS 32
FIGURE 6 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS 34
FIGURE 7 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID 35
FIGURE 8 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: MARKET TESTING TYPE COVERAGE GRID 37
FIGURE 9 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS 38
FIGURE 10 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: SEGMENTATION 42
FIGURE 11 INCREASE IN THE AWARENESS ABOUT LEUKEMIA IS EXPECTED TO DRIVE THE NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET IN THE FORECAST PERIOD 43
FIGURE 12 INSTRUMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET IN 2023 & 2030 43
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA ACUTE LYMPHOCYTIC/ LYMPHOBLASTIC (ALL) LEUKEMIA DIAGNOSTICS MARKET 53
FIGURE 14 NORTH AMERICA LEUKEMIA INCIDENCE (BOTH SEXES) 56
FIGURE 15 FIVE YEARS PREVALENCE LEUKEMIA INCIDENCE (BOTH SEXES) 57
FIGURE 16 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2022 63
FIGURE 17 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION) 64
FIGURE 18 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY PRODUCT TYPE, CAGR (2023-2030) 64
FIGURE 19 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET : BY PRODUCT TYPE, LIFELINE CURVE 65
FIGURE 20 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY TEST TYPE, 2022 75
FIGURE 21 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY TEST TYPE, 2023-2030 (USD MILLION) 76
FIGURE 22 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY TEST TYPE, CAGR (2023-2030) 76
FIGURE 23 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY TEST TYPE, LIFELINE CURVE 77
FIGURE 24 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY CANCER TYPE, 2022 85
FIGURE 25 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY CANCER TYPE, 2023-2030 (USD MILLION) 86
FIGURE 26 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY CANCER TYPE, CAGR (2023-2030) 86
FIGURE 27 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY CANCER TYPE, LIFELINE CURVE 87
FIGURE 28 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY AGE GROUP, 2022 92
FIGURE 29 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY AGE GROUP, 2023-2030 (USD MILLION) 93
FIGURE 30 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY AGE GROUP, CAGR (2023-2030) 93
FIGURE 31 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY AGE GROUP, LIFELINE CURVE 94
FIGURE 32 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY GENDER, 2022 100
FIGURE 33 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY GENDER, 2023-2030 (USD MILLION) 101
FIGURE 34 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY GENDER, CAGR (2023-2030) 101
FIGURE 35 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET : BY GENDER, LIFELINE CURVE 102
FIGURE 36 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY END USER, 2022 106
FIGURE 37 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY END USER, 2023-2030 (USD MILLION) 107
FIGURE 38 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY END USER, CAGR (2023-2030) 107
FIGURE 39 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE 108
FIGURE 40 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2022 114
FIGURE 41 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 115
FIGURE 42 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 115
FIGURE 43 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, LIFELINE CURVE 116
FIGURE 44 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: SNAPSHOT (2022) 121
FIGURE 45 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY COUNTRY (2022) 123
FIGURE 46 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 123
FIGURE 47 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 124
FIGURE 48 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: PRODUCT TYPE (2023-2030) 124
FIGURE 49 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 150